Business · 07/04/2022Updated: 10/17/2026 · 1 min read
FDA Clears PEPCID Oral Suspension for Approval
Summary
The US Food and Drug Administration has determined that the 40mg/5mL oral suspension of famotidine, marketed as PEPCID, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →